Lv6
1640 积分 2025-05-20 加入
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
7天前
已完结
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
1个月前
已完结
Factors that can make overall survival unreliable as a clinical trial outcome – Authors' reply
1个月前
已完结
Overall survival assessment in cancer drug trials: a luxury or a necessity?
1个月前
已完结
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti‐CD20): a retrospective cohort analysis
1个月前
已完结
Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma
1个月前
已完结
Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome
1个月前
已完结
Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis
3个月前
已完结
Treatment strategies for patients with diffuse large B-cell lymphoma
3个月前
已完结
Treatment strategies for patients with diffuse large B-cell lymphoma
3个月前
已完结
皖公网安备34019202002308
